AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8845036 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intravaginal vaccination with whole cell/B subunit (CTB) cholera vaccine mixed with eldexomer gel
Number of subjects: 14
Study 1341234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: approximately 3.0 g d‐1 sodium sulphate in juice
Number of subjects: 69
Study 1341234 — intervention group
Group type: COMPARATOR
Intervention: Group A: placebo of fruit juice
Number of subjects: 69
Study 1341234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 30 g d‐1 supplementary dietary fibre as wheat bran in bread
Number of subjects: 69
Study 2993892 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare program; includes a comprehensive 6-month training curriculum and self-help fellowship meetings.
Number of subjects: 0
Study 2993892 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control condition; details not specified.
Number of subjects: 0
Study 30693094 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + peer befriending
Number of subjects: 60
Study 30693094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 28958125 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-sensitive patient information materials (PIM)
Number of subjects: 29
Study 28958125 — intervention group
Group type: COMPARATOR
Intervention: Standard translated material
Number of subjects: 29
Study 29465890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 60
Study 29465890 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 60
Study 23671001 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI)
Number of subjects: 0
Study 23671001 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal RAI users
Number of subjects: 0
Study 23671001 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal RAI users
Number of subjects: 0
Study 22891797 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 2 g/day as adjunct maintenance treatment
Number of subjects: 149
Study 22891797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 20451687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week
Number of subjects: 44
Study 20451687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 300 mg/week
Number of subjects: 44
Study 20451687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17094172 — intervention group
Group type: EXPERIMENTAL
Intervention: Water extract of Hibiscus sabdariffa (300 mL daily for 3 days)
Number of subjects: 0
Study 17094172 — intervention group
Group type: COMPARATOR
Intervention: Control (no beverage)
Number of subjects: 0
Study 18598992 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 18598992 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete endoscopic healing in response to infliximab
Number of subjects: 0
Study 18598992 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatments with distal colonoscopy
Number of subjects: 0
Study 18598992 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 18598992 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-viral treatment added to conventional treatments
Number of subjects: 0
Study 15309458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked cherry tomatoes
Number of subjects: 5
Study 15309458 — intervention group
Group type: COMPARATOR
Intervention: Fresh cherry tomatoes
Number of subjects: 5
Study 11769605 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) emulsion
Number of subjects: 30
Study 11769605 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) emulsion
Number of subjects: 30
Study 9362378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 0.9 MIU
Number of subjects: 33
Study 9362378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 1.8 MIU
Number of subjects: 33
Study 9362378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 3.6 MIU
Number of subjects: 33
Study 9362378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 5.4 MIU
Number of subjects: 33
Study 9362378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment overall
Number of subjects: 33
Study 8213871 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching group (eight-session physical diagnosis course on the cardiology-patient simulator 'Harvey')
Number of subjects: 56
Study 8213871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplemental teaching)
Number of subjects: 56
Study 3777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 44
Study 3777458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 44
Study 11915784 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH CHO diet (greater than 70% of daily energy intake from CHO)
Number of subjects: 7
Study 11915784 — intervention group
Group type: COMPARATOR
Intervention: LOW CHO diet (less than 10% of daily energy intake from CHO)
Number of subjects: 7
Study 31768402 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced First Breath program (4 in-home counseling visits, 3 postpartum counseling calls, support to others in the home, incentives totaling $100)
Number of subjects: 185
Study 31768402 — intervention group
Group type: COMPARATOR
Intervention: Standard First Breath program (control group)
Number of subjects: 185
Study 31768402 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced First Breath program (intent-to-treat analysis)
Number of subjects: 185
Study 31768402 — intervention group
Group type: COMPARATOR
Intervention: Standard First Breath program (intent-to-treat analysis)
Number of subjects: 185
Study 29198623 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 425
Study 29198623 — intervention group
Group type: COMPARATOR
Intervention: Axillary thoracotomy
Number of subjects: 425
Study 27588816 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoSanTM
Number of subjects: 50
Study 27588816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24686911 — intervention group
Group type: EXPERIMENTAL
Intervention: High cue condition
Number of subjects: 8
Study 24686911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cue condition
Number of subjects: 8
Study 22585590 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6 mg)
Number of subjects: 32
Study 22585590 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3 mg)
Number of subjects: 32
Study 22585590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19833898 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect self-affirmations following intelligence threats
Number of subjects: 4
Study 19833898 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct self-affirmations following belonging threats
Number of subjects: 4
Study 19833898 — intervention group
Group type: COMPARATOR
Intervention: Indirect affirmation strategies
Number of subjects: 4
Study 17376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb preventive treatment group (3.0%)
Number of subjects: 1090
Study 17376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition support subgroup (0.9%)
Number of subjects: 1090
Study 17376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral combined parenteral nutrition support subgroup (2.1%)
Number of subjects: 1090
Study 17376267 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition support subgroup
Number of subjects: 1090
Study 17376267 — intervention group
Group type: COMPARATOR
Intervention: No nutrition support subgroup
Number of subjects: 1090
Study 15946863 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous self-reported rating of emotion experience
Number of subjects: 0
Study 15946863 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing of amusing and sad films
Number of subjects: 0
Study 12030958 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of proton pump inhibitor
Number of subjects: 2391
Study 12030958 — intervention group
Group type: COMPARATOR
Intervention: Single dose of proton pump inhibitor
Number of subjects: 2391
Study 12669740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0
Study 7770713 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ORS containing bicarbonate
Number of subjects: 60
Study 7770713 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate-free ORS
Number of subjects: 60
Study 2189319 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Number of subjects: 200
Study 2189319 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Number of subjects: 200
Study 2189319 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of intranasal flunisolide
Number of subjects: 200
Study 2189319 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of intranasal flunisolide
Number of subjects: 200
Study 43164 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (138 +/- 13 mg daily)
Number of subjects: 0
Study 43164 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (234 +/- 22 mg daily)
Number of subjects: 0
Study 43164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (24 +/- 2 mg daily)
Number of subjects: 0
Study 43164 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (308 +/- 34 mg daily)
Number of subjects: 0
Study 30777131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Interleukin-2 (HD IL-2)
Number of subjects: 57
Study 30101539 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV/FTC/TAF
Number of subjects: 1505
Study 30101539 — intervention group
Group type: COMPARATOR
Intervention: RPV/FTC/TDF
Number of subjects: 1505
Study 30101539 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 1505
Study 26758744 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs + IRS
Number of subjects: 770
Study 26758744 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs alone
Number of subjects: 770
Study 26758744 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS alone
Number of subjects: 770
Study 26758744 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 770
Study 25245491 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral self-efficacy
Number of subjects: 317
Study 25245491 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived referral norms
Number of subjects: 317
Study 25245491 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral anticipatory anxiety
Number of subjects: 317
Study 25245491 — intervention group
Group type: COMPARATOR
Intervention: Length of RA service and time spent on campus
Number of subjects: 317
Study 23003122 — intervention group
Group type: COMPARATOR
Intervention: 3-W laser beam for 10 sec (Group 2)
Number of subjects: 60
Study 23003122 — intervention group
Group type: COMPARATOR
Intervention: 1% sodium hypochlorite for 15 min (Group 4)
Number of subjects: 60
Study 23003122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite for 15 min followed by 3-W laser beam for 10 sec (Group 3)
Number of subjects: 60
Study 23003122 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 60
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5mg
Number of subjects: 79
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Number of subjects: 79
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Number of subjects: 79
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30mg
Number of subjects: 79
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40mg
Number of subjects: 79
Study 20062915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (all doses)
Number of subjects: 79
Study 20062915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 17432678 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SF) 1 mL/kg
Number of subjects: 24
Study 17432678 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SF)
Number of subjects: 24
Study 17432678 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 24
Study 15632922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous closed drainage
Number of subjects: 14
Study 15632922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter (only 8 patients had this intervention)
Number of subjects: 14
Study 14571614 — intervention group
Group type: EXPERIMENTAL
Intervention: Luohuo Capsule (LHC)
Number of subjects: 90
Study 14571614 — intervention group
Group type: COMPARATOR
Intervention: Beijing Hypotensive No. 0 (Control)
Number of subjects: 90
Study 10973392 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 250 microg subcutaneously every 8 hours for 7 days
Number of subjects: 211
Study 10973392 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 211
Study 8804239 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) recombinant erythropoietin (rH-EPO)
Number of subjects: 49
Study 8804239 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) recombinant erythropoietin (rH-EPO)
Number of subjects: 49
Study 1536396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 6 micrograms.kg‐1 during fibreoptic intubation
Number of subjects: 60
Study 1536396 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 6 micrograms.kg‐1 during Macintosh intubation
Number of subjects: 60
Study 6376918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phosphorus, low-protein diet (7.0 mg phosphorus and 0.5 g protein per kg body weight)
Number of subjects: 20
Study 6376918 — intervention group
Group type: COMPARATOR
Intervention: Control diet (12 mg phosphorus and 0.8 g protein per kg body weight)
Number of subjects: 20
Study 30576781 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Dietary Antioxidant Index (CDAI)
Number of subjects: 894
Study 30576781 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake
Number of subjects: 894
Study 30576781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake
Number of subjects: 894
Study 30576781 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, systolic blood pressure, and triglycerides as predictors
Number of subjects: 894
Study 30576781 — intervention group
Group type: COMPARATOR
Intervention: CDAI in men
Number of subjects: 894
Study 29573473 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg s.c. once monthly for 12 months
Number of subjects: 7180
Study 29573473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7180
Study 27483318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-specific questionnaire for assessing water intake from beverages
Number of subjects: 160
Study 27483318 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 160
Study 24774860 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol supplementation (0.5 μg/day for one year)
Number of subjects: 484
Study 24774860 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without depression)
Number of subjects: 484
Study 22476724 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a pure-tone standard at a frequency within their region of normal hearing
Number of subjects: 70
Study 22476724 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a pure-tone standard within the region of hearing loss
Number of subjects: 70
Study 22476724 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency discrimination training with a high-pass harmonic complex tone spanning a region of hearing loss
Number of subjects: 70
Study 22476724 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 21244729 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 70
Study 21244729 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 70
Study 17920715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF) - 58 Gy in 40 equal fractions given twice per day
Number of subjects: 331
Study 17920715 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 51 Gy in 20 equal daily fractions
Number of subjects: 331
Study 17920715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HF)
Number of subjects: 331
Study 17920715 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 331
Study 16033855 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (6 sessions/wk of 3 h each)
Number of subjects: 77
Study 16033855 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (three sessions/wk of 4 h each)
Number of subjects: 77
Study 12241539 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0.147 nmol.min(‐1).kg(‐1))
Number of subjects: 16
Study 12241539 — intervention group
Group type: COMPARATOR
Intervention: Emagel infusion (control)
Number of subjects: 16
Study 9737807 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg once daily
Number of subjects: 229
Study 9737807 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 200 mg twice daily
Number of subjects: 229
Study 9737807 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 800 mg once daily
Number of subjects: 229
Study 9737807 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg twice daily
Number of subjects: 229
Study 9737807 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (all doses)
Number of subjects: 229
Study 9737807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 7802188 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine A (AVL 912 co-oxylite co-oximeter)
Number of subjects: 96
Study 7802188 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine B (AVL 912 co-oxylite co-oximeter)
Number of subjects: 96
Study 7802188 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine C (IL-282 co-oximeter)
Number of subjects: 96
Study 7802188 — intervention group
Group type: EXPERIMENTAL
Intervention: Machines A and B (AVL 912 co-oxylite co-oximeters)
Number of subjects: 96
Study 3188983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 131
Study 3188983 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 131
Study 30846389 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training using elastic tubing (GET)
Number of subjects: 28
Study 30846389 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training (GCT)
Number of subjects: 28
Study 29986720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 24
Study 29986720 — intervention group
Group type: COMPARATOR
Intervention: Non-Ketogenic diet (NKD)
Number of subjects: 24
Study 29986720 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 25795907 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily
Number of subjects: 383
Study 25795907 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous tofacitinib 10 mg twice daily
Number of subjects: 383
Study 25795907 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 383
Study 25795907 — intervention group
Group type: EXPERIMENTAL
Intervention: withdrawn tofacitinib
Number of subjects: 383
Study 25795907 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous tofacitinib
Number of subjects: 383
Study 25239484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0, 14
Number of subjects: 100
Study 25239484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0 and 28
Number of subjects: 100
Study 25239484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL vaccine subcutaneously at days 0, 14, and 28
Number of subjects: 100
Study 25239484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mL vaccine subcutaneously at days 0, 14, and 28
Number of subjects: 100
Study 22348304 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppository (100 mg) plus saline 0.9% (placebo)
Number of subjects: 550
Study 22348304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository (100 mg) plus intravenous papaverine hydrochloride (1.5 mg/kg up to 120 mg)
Number of subjects: 550
Study 19394643 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drained group
Number of subjects: 101
Study 19394643 — intervention group
Group type: COMPARATOR
Intervention: Drained group
Number of subjects: 101
Study 17542768 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 0
Study 15533540 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention group (smoking cessation groups)
Number of subjects: 2168
Study 11896091 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage containing 90 mg of isoflavones
Number of subjects: 123
Study 11896091 — intervention group
Group type: COMPARATOR
Intervention: Placebo rice beverage
Number of subjects: 123
Study 11896091 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 123
Study 9808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral clodronate (800 mg)
Number of subjects: 46
Study 9808483 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intranasal calcitonin (200 IU)
Number of subjects: 46
Study 9808483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 46
Study 7663595 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pain flowsheet documentation
Number of subjects: 61
Study 7663595 — intervention group
Group type: COMPARATOR
Intervention: Traditional charting of pain presence or absence
Number of subjects: 61